Editas Medicine EDIT Institutional Ownership

Updated Nov 4, 2026

Editas Medicine, Inc. (NASDAQ:EDIT) appeared in the 13F filings of 217 institutional investors for the quarter ended June 30, 2026.

• Total shares held in Editas Medicine rose 130.01% versus Q1 2026, while the number of holders rose 11.86% versus Q2 2025.
• Of the 217 holders, 112 added to their positions, 41 reduced their stakes and 64 left their positions unchanged in Q2 2026.
• Institutional investors held 119.3Mn shares of Editas Medicine in total at the end of Q2 2026, up 67.43Mn from the prior quarter and up 80.03Mn from a year earlier.
• TCG Crossover Management, LLC led 13F holders of EDIT with 11.11Mn shares as of June 30, 2026.
• The biggest increases in EDIT positions during Q2 2026 came from Goldman Sachs Group Inc (+2.06Mn shares), Vanguard Capital Management LLC (+1.94Mn shares), Opaleye Management Inc. (+1.93Mn shares), Marshall Wace, LLP (+1.83Mn shares) and BlackRock, Inc. (+1.33Mn shares).
• The largest position reductions in EDIT for Q2 2026 were by Renaissance Technologies LLC (-1.5Mn shares), Nuveen, LLC (-1.46Mn shares), Citadel Advisors LLC (-449.63K shares), Jacobs Levy Equity Management, Inc (-444.95K shares) and Acadian Asset Management LLC (-418.71K shares).
• Editas Medicine's 10 largest institutional shareholders as of Q2 2026 were TCG Crossover Management, LLC (11.11Mn shares), BlackRock, Inc. (10.59Mn shares), Ra Capital Management, L.P. (8.89Mn shares), Commodore Capital LP (8.89Mn shares), ADAR1 Capital Management, LLC (8.89Mn shares), Vanguard Capital Management LLC (6.14Mn shares), Paradigm Biocapital Advisors LP (5.59Mn shares), Opaleye Management Inc. (3.86Mn shares), Vanguard Portfolio Management LLC (3.6Mn shares) and Woodline Partners LP (3.56Mn shares), per Business Quant data.